SCHEMBL5016332

SCHEMBL5016332

Nc1cc(-c2ccco2)nc(-c2nccs2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 1/20 0.55
CYP19A1 P11511 1/20 0.49
MAPT P10636 4/20 0.48
HSD17B10 Q99714 2/20 0.48
ALDH1A1 P00352 5/20 0.46
POLB P06746 2/20 0.46
ADORA2A P29274 8/20 0.44
ADORA1 P30542 7/20 0.44
ADORA2B P29275 3/20 0.44
KDM4E B2RXH2 4/20 0.44
PKM P14618 1/20 0.44
RAB9A P51151 1/20 0.44
GFER P55789 1/20 0.44
KDM4C Q9H3R0 1/20 0.44
HSP90AA1 P07900 1/20 0.43
TOP1 P11387 1/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
KMT2A Q03164 1/20 0.42
MCL1 Q07820 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5016124 0.89 ADORA2A (0.50) MYCCYP19A1MAPTHSD17B10ALDH1A1
SCHEMBL5017656 0.84 MYC (0.52) MYCCYP19A1MAPTHSD17B10ALDH1A1
SCHEMBL5024950 0.84 MYC (0.55) MYCCYP19A1MAPTHSD17B10ALDH1A1
SCHEMBL1489975 0.81 HSP90AA1 (0.54) HSD17B10ALDH1A1ADORA2AADORA1RAB9A
SCHEMBL5017694 0.79 ADORA2A (0.56) MAPTHSD17B10ALDH1A1POLBADORA2A
SCHEMBL5022387 0.76 KDM4E (0.66) CYP19A1MAPTHSD17B10ALDH1A1POLB
SCHEMBL5349589 0.76 MYC (0.49) MYCCYP19A1MAPTHSD17B10ALDH1A1
SCHEMBL13147752 0.74 CYP19A1 (0.48) CYP19A1MAPTHSD17B10ALDH1A1POLB
SCHEMBL5017647 0.74 SMN1; SMN2 (0.54) CYP19A1MAPTHSD17B10ALDH1A1ADORA2A
SCHEMBL5016206 0.74 ADORA2A (0.47) MYCCYP19A1MAPTHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US claimed
JP-2007514003-A 2007-05-31 JP claimed
CN-1953975-A 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists ALMIRALL PRODESFARMA AG (CH) 2007-04-25 CN claimed
EP-1697351-A1 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma AG (CH) 2006-09-06 EP claimed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO claimed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
CN-1953975-A 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists ALMIRALL PRODESFARMA AG (CH) 2007-04-25 CN disclosed
EP-1697351-A1 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma AG (CH) 2006-09-06 EP disclosed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO disclosed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 MYC 4358/4885CYP19A1 3285/4885MAPT 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.